Amgen

This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (August 2020) (Learn how and when to remove this message)

Amgen Inc.

Headquarters in Thousand Oaks, California
Formerly	Applied Molecular Genetics (1980–1983)
Company type	Public
Traded as	Nasdaq: AMGN Nasdaq-100 component DJIA component S&P 100 component S&P 500 component
ISIN	US0311621009
Industry	Biotechnology
Founded	April 8, 1980; 44 years ago (1980-04-08)
Headquarters	Thousand Oaks, California, U.S.
Key people	Robert A. Bradway (chairman, president & CEO)
Products	Aimovig Aranesp Blincyto Epogen Kineret Enbrel Kyprolis Neulasta Neupogen Nplate Parsabiv Prolia Repatha Sensipar/Mimpara Vectibix Xgeva
Revenue	US$28.19 billion (2023)
Operating income	US$7.897 billion (2023)
Net income	US$6.717 billion (2023)
Total assets	US$97.15 billion (2023)
Total equity	US$6.232 billion (2023)
Number of employees	c. 26,700 (2023)
Website	amgen.com
Footnotes / references [1][2]

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.^[3][4] One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.^[5]

The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company is listed on the Nasdaq Global Select Market under the ticker symbol "AMGN", as well as a component of the Nasdaq-100, the Dow Jones Industrial Average, and the S&P 100 and 500 indices.